Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18682508 | 0.94 | ESR2 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9979794 | 0.87 | AOC3 (0.34) | AOC3SLC2A1TSHRESR2 | |
| SCHEMBL13651984 | 0.80 | KMT2A (0.47) | ALDH1A1MAPK1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL19728209 | 0.80 | CA1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19728201 | 0.80 | CA1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL435441 | 0.80 | CA1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3695690 | 0.80 | CA1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL120187 | 0.80 | CA12 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11938484 | 0.80 | CA1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11938486 | 0.80 | CA1 (0.58) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106317176-B | Double indoles-tripeptide derivatives, synthesis, antithrombotic acitivity and the application for preparing antithrombotic agents | 首都医科大学 | 2019-07-26 | — | — | CN | claimed |
| US-9884826-B2 | Sulfonamide compounds and uses as TNAP inhibitors | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-02-06 | — | — | US | disclosed |
| US-9796680-B2 | Glucocerebrosidase modulators and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| US-20170029379-A1 | GLUCOCEREBROSIDASE MODULATORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2017-02-02 | — | — | US | disclosed |
| CN-102659837-B | Solanesol phosphamide derivatives and their preparation method and use | UNIV SHIJIAZHUANG | 2015-07-15 | — | — | CN | disclosed |
| CN-102659841-B | Polyphenol phosphamide derivative, and preparation method and application thereof | UNIV SHIJIAZHUANG | 2015-03-25 | — | — | CN | disclosed |
| WO-2007092213-A2 | INHIBITORS OF E1 ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1506175-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097609-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029379-A1 | GLUCOCEREBROSIDASE MODULATORS AND USES THEREOF | GBA1, GAA, GBA2 | CA12 4241/4885CA1 4240/4885CA2 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.